4 completed, 2 recruiting, 1 not yet recruiting, 1 unknown. 9 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 4, Recruiting 2, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow efgartigimod alfa: new trials by email Literature Review of efgartigimod alfa trials Research Report on efgartigimod alfa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis Nipocalimab, Efgartigimod - Myasthenia Gravis | Phase 3 | Recruiting | Janssen Research & Development, LLC | 115 | 2026-01-05 | 2026-11-03 |
| Efgartigimod for the Treatment of Guillain-Barré Syndrome efgartigimod - Guillain-Barre Syndrome (GBS) | Phase 2 / Phase 3 | Not yet recruiting | Zhongming Qiu | 20 | 2025-04-13 | 2025-03-20 |
| Efgartigimod in IVIG Dependent Myasthenia Gravis Patients efgartigimod administration - Myasthaenia Gravis | Phase 3 | Recruiting | Clinique Neuro-Outaouais | 30 | 2025-02-06 | 2026-10-22 |
| Seronegative Myasthenia Gravis - Efgartigimod IV efgartigimod - Efgartigimod, Generalized Myasthenia Gravis | Phase 3 | Unknown | University Health Network, Toronto | 30 | 2023-06-01 | 2024-09-19 |
| A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP) efgartigimod, Placebo - Primary Immune Thrombocytopenia (ITP) | Phase 3 | Withdrawn | argenx | 2020-06-29 | 2020-09-14 | |
| A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). efgartigimod - Primary Immune Thrombocytopenia | Phase 3 | Completed | argenx | 101 | 2020-06-02 | 2026-03-16 |
| A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). efgartigimod, Placebo - Primary Immune Thrombocytopenia | Phase 3 | Completed | argenx | 131 | 2019-12-16 | 2025-03-13 |
| A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. ARGX-113 - Generalized Myasthenia Gravis | Phase 3 | Completed | argenx | 151 | 2019-03-01 | 2023-07-14 |
| An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness ARGX-113, Placebo - Generalized Myasthenia Gravis | Phase 3 | Completed | argenx | 167 | 2018-08-22 | 2022-02-08 |
Myasthenia Gravis (5) · Purpura, Thrombocytopenic, Idiopathic (3) · Guillain-Barre Syndrome (1)
argenx (5) · Clinique Neuro-Outaouais (1) · Janssen Research & Development, LLC (1) · University Health Network, Toronto (1) · Zhongming Qiu (1)
Germany (5) · United States (5) · Belgium (4) · Canada (4) · Czechia (4) · France (4) · Georgia (4) · Hungary (4) · Italy (4) · Japan (4) · Netherlands (4) · Poland (4) · Russia (4) · Spain (3) · United Kingdom (3)
Antonio Guglietta, MD (1) · Sabine Coppieters, MD (1) · Vera Bril, MD (1)
PMID 34146511, PMID 37778358, PMID 38318236, PMID 39068745, PMID 41180124, PMID 41517964, PMID 42234197
2018 (2), 2019 (2), 2025 (1)